BIOLASE, Inc. Quarterly report pursuant to Section 13 or 15(d)

Convertible Redeemable Preferred Stock And Stockholders' Equity - Summary our stock warrants measured at fair value (Details)

Convertible Redeemable Preferred Stock And Stockholders' Equity - Summary our stock warrants measured at fair value (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Temporary Equity And Stockholders Equity [Line Items]
Beginning Balance, December 31, 2023	$ 1,363
Fair Value Adjustment	556	$ 0
Ending Balance, March 31, 2024	3,780
Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Beginning Balance, December 31, 2023	1,363
Additions	3,851
Exercises	(1,960)
Fair Value Adjustment	526
Ending Balance, March 31, 2024	3,780
Series H Warrants [Member] \| Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Beginning Balance, December 31, 2023	620
Fair Value Adjustment	23
Ending Balance, March 31, 2024	643
Series J Warrants [Member] \| Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Beginning Balance, December 31, 2023	743
Fair Value Adjustment	(15)
Ending Balance, March 31, 2024	728
Class A Common Warrants [Member] \| Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Additions	2,280
Exercises	(1,960)
Fair Value Adjustment	85
Ending Balance, March 31, 2024	405
Class B Common Warrants [Member] \| Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Additions	1,379
Fair Value Adjustment	381
Ending Balance, March 31, 2024	1,760
Investor Warrants \| Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Additions	192
Fair Value Adjustment	52
Ending Balance, March 31, 2024	$ 244